Toyobo Co., Ltd.

Toyobo Co., Ltd.

8.20
EUR
-0.25
(-2.96%)
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
3,956.77
3,956.51
3,917.06
3,711.32
3,730.24
3,793.01
3,824.66
3,798.16
4,227.46
4,499.31
4,702.88
4,789.21
4,778.49
- -
Basic EPS, GAAP
91.77
91.42
114.33
106.38
146.93
-6.79
155.12
47.3
144.75
-7.37
27.87
22.73
126.66
- -
Free Cash Flow per Basic Share
40.3
24.31
173.22
109.49
18.69
-184.72
150.88
84.8
-135.19
-352.82
-397.72
-171.43
180.03
- -
Dividend per Share
35
35.08
35.04
35.05
35.04
39.99
39.99
39.96
39.98
40
40.09
40
39.84
- -
Book Value per Share
1,602.85
1,779.47
1,767.46
1,889.81
2,034.04
1,989.29
2,003
2,090.46
2,192.16
2,146.47
2,236.49
2,215.11
2,417.3
2,417.3
Tangible Book Value per Share
1,568.73
1,742.18
1,723.98
1,842.65
1,989.15
1,948.13
1,950.74
2,037.86
2,143.71
2,094.02
2,183.48
2,158.04
2,362.41
2,362.41
Basic Weighted Avg Shares
89
89
89
89
89
89
89
89
89
89
88
88
88
88
Sales/Revenue/Turnover
351,577
351,279
347,763
329,487
331,148
336,698
339,607
337,406
375,720
399,921
414,265
422,032
421,563
- -
Operating Margin (%)
5.97
5.86
6.65
7.08
7.22
6.45
6.71
7.9
7.57
2.52
2.17
3.95
6.62
- -
Depreciation Expense
14,038
14,916
14,434
14,939
15,666
15,823
17,005
19,095
20,080
19,050
19,806
22,698
24,631
- -
Net Income, GAAP
8,154
8,117
10,150
9,444
13,044
-603
13,774
4,202
12,865
-655
2,455
2,003
11,174
- -
Effective Tax Rate (%)
34.03
32.67
36.72
35.24
28.76
895.1
32.49
58.58
18.48
231.86
35.92
27.47
26.49
- -
Profit Margin (%)
2.32
2.31
2.92
2.87
3.94
-0.18
4.06
1.25
3.42
-0.16
0.59
0.47
2.65
- -
Working Capital
24,048
50,357
55,943
59,428
61,461
61,357
84,095
81,519
92,564
96,633
89,585
107,175
112,948
112,948
LT Debt
90,831
110,425
103,697
95,440
88,188
99,009
130,851
122,046
125,681
114,099
145,637
181,343
175,345
175,345
Total Equity
145,116
161,086
160,102
170,910
184,515
181,226
182,636
188,635
197,149
221,423
230,086
232,044
251,995
251,995
Return on Invested Capital (%)
4.44
4.26
4.42
4.55
5.1
-51.27
4.41
3.04
6.13
-3.19
1.25
2.5
4.1
- -
Return on Capital (%)
2.63
2.81
3.34
3.25
4.19
-3.2
4.34
1.83
3.88
-0.54
0.48
0.08
2.05
- -
Return on Common Equity (%)
5.82
5.41
6.45
5.82
7.49
-0.34
7.77
2.31
6.76
-0.34
1.27
1.02
5.47
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
65,819
79,126
LT Borrowings
- -
189,748
175,345
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
88
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
255,658
270,543
Cash, Cash Equivalents & STI
- -
26,044
31,107
Accounts Receivable, Net
- -
79,341
88,208
Inventories
- -
125,997
128,055
Total Current Liabilities
- -
140,952
157,595
Payables & Accruals
- -
- -
- -
ST Debt
- -
65,819
79,126
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.72%
6.04%
8.6%
Free Cash Flow
-178.23%
-69.76%
-205.13%
Net Income, GAAP
-246.15%
13.14%
457.86%
Sales/Revenue/Turnover
2.03%
4.63%
-0.11%
Total Cash Common Dividend
1.31%
-0.2%
-0.28%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
97,058
102,361
107,904
106,942
414,265
2025
- -
- -
- -
- -
422,032
2026
- -
- -
- -
- -
421,563

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.77
28.6
-4.97
10.01
27.87
2025
- -
- -
- -
- -
22.73
2026
- -
- -
- -
- -
126.66

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
40.09
2025
- -
- -
- -
- -
40
2026
- -
- -
- -
- -
39.84

Company Description

CEO
Ikuo Takeuchi
Full Time Employees
9,398
Sector
Process industries
Industry
Chemicals: specialty
Address
Osaka Umeda Twin Towers South Osaka OS Japan 530-0001
IPO Date
May 16, 1949
Business
Toyobo Co., Ltd. manufactures and sells a broad range of high-performance materials including industrial films, packaging films, environmental and functional materials, healthcare products, textiles, and trading services. Its core product segments encompass films and functional polymers, such as industrial and packaging films including the XENOMAX brand; healthcare products including bioproducts, medical materials, pharmaceutical contracting, antithrombogenic polymers, nerve regeneration conduits, and bone regeneration materials; textile products like airbags, functional textiles designed for mobility tech, indutech, sportech, buildtech, hometech, clothtech, and meditech industries; and real estate leasing and management. Toyobo serves global markets, particularly Japan and Southeast Asia, and operates subsidiaries such as Toyobo MC Corporation and Toyobo STC. Founded in 1882 and headquartered in Osaka, Japan, Toyobo has recently undertaken significant strategic moves. In 2024 and 2025, Toyobo launched new integrated production plants for artificial kidney hollow fibers and expanded membranes for acute blood purification and biomaterials. It also enhanced production capacity with new equipment for mold releasing films used in MLCC manufacturing and polarizer protective films for LCDs. In June 2025, Toyobo entered a joint research and development agreement related to biomanufacturing with DMC Biotechnologies Inc. Meanwhile, Toyobo MC Corporation developed and exhibited environmental solutions equipment in 2025, including VOC treatment and recovery equipment, catalytic oxidation apparatus, and combustion apparatus. Furthermore, in late 2025, Toyobo decided to acquire its subsidiary Toyobo STC to consolidate operations. In 2022, Toyobo established a joint venture with Mitsubishi Corporation whereby Mitsubishi acquired certain Toyobo operations related to functional materials including polymerization development, engineering plastics (VYLON® and HARDLEN®), fine chemicals, water treatment membranes, and high-performance fibers. These recent expansions and partnerships reinforce Toyobo’s position as a leading innovator in high-performance materials and functional textiles, supported by robust research and development efforts focused on biotechnology, polymer technology, and environmental solutions, addressing diverse industries such as healthcare, electronics, automotive, and industrial sectors across Japan and international markets. The company maintains a strong presence in Japan while expanding sales notably in Southeast Asia, reflecting its global growth strategy and continued innovation in advanced materials.